Eritoran Tetrasodium (E5564) Treatment for Sepsis: Review of Preclinical and Clinical Studies

Overview

Journal Expert Opin Drug Metab Toxicol

Publisher Informa Healthcare

Specialties Endocrinology
Pharmacology
Toxicology

Date 2011 Feb 18

PMID 21323610

Citations 79

Authors

Amisha Barochia

Steven Solomon

Xizhong Cui

Charles Natanson

Peter Q Eichacker

Affiliations

Soon will be listed here.

Abstract

Introduction: Sepsis remains a leading cause of death worldwide. Despite years of extensive research, effective drugs that inhibit the pro-inflammatory effects of lipopolysaccharide (LPS) and improve outcome when added to conventional sepsis treatments are lacking. Eritoran tetrasodium (E5564) is a promising candidate therapy for sepsis belonging to a new class of such drugs which inhibit LPS-induced inflammation by blocking toll-like receptor 4.

Areas Covered: This review focuses on the rationale for the use of eritoran tetrasodium in sepsis as well as on its pharmacokinetics, pharmacodynamics, efficacy and safety. Preclinical and clinical studies from a MEDLINE/PubMed literature search in August 2010 with the search terms 'eritoran' and 'E5564' are discussed.

Expert Opinion: Preclinical in vitro and in vivo studies of eritoran tetrasodium indicate it can limit excessive inflammatory mediator release associated with LPS and improve survival in sepsis models. While early clinical results are promising, its efficacy and safety for treating patients with sepsis are currently under investigation. Even if the ongoing Phase III clinical trial enrolling patients with severe sepsis and increased risk of death shows benefit from eritoran, questions remain and confirmatory studies would be necessary to define its clinical usage.

Citing Articles

miR-6089 Alleviates Inflammation and Cell Apoptosis Through Modulating the TLR4 Pathway in Mite-Sensitized Allergic Rhinitis.

Qiu C, Bi J, Cui X, Chen R, Luan Z, Guo Y J Inflamm Res. 2025; 18:3243-3254.

PMID: 40065904 PMC: 11892734. DOI: 10.2147/JIR.S497005.

Sepsis: the evolution of molecular pathogenesis concepts and clinical management.

Feng Z, Wang L, Yang J, Li T, Liao X, Kang Y MedComm (2020). 2025; 6(3):e70109.

PMID: 39991626 PMC: 11847631. DOI: 10.1002/mco2.70109.

Endogenous Ligands of TLR4 in Microglia: Potential Targets for Related Neurological Diseases.

Chen B, Di B Curr Drug Targets. 2024; 25(14):953-970.

PMID: 39234911 DOI: 10.2174/0113894501316051240821060249.

Enhancing acute inflammatory and sepsis treatment: superiority of membrane receptor blockade.

Mun S, Cho E, Kim H, Gil W, Yang C Front Immunol. 2024; 15:1424768.

PMID: 39081318 PMC: 11286478. DOI: 10.3389/fimmu.2024.1424768.

Evolving Paradigms in Sepsis Management: A Narrative Review.

Kim M, Choi E, Choi E Cells. 2024; 13(14.

PMID: 39056754 PMC: 11274781. DOI: 10.3390/cells13141172.

References

Rossignol D, Wasan K, Choo E, Yau E, Wong N, Rose J . Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother. 2004; 48(9):3233-40. PMC: 514793. DOI: 10.1128/AAC.48.9.3233-3240.2004. View

Wong Y, Rossignol D, Rose J, Kao R, Carter A, Lynn M . Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol. 2003; 43(7):735-42. View

Aderem A, Ulevitch R . Toll-like receptors in the induction of the innate immune response. Nature. 2000; 406(6797):782-7. DOI: 10.1038/35021228. View

Hawkins L, Christ W, Rossignol D . Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem. 2004; 4(11):1147-71. DOI: 10.2174/1568026043388123. View

Golenbock D, Leggett J, Rasmussen P, Craig W, Raetz C, Proctor R . Lipid X protects mice against fatal Escherichia coli infection. Infect Immun. 1988; 56(4):779-84. PMC: 259370. DOI: 10.1128/iai.56.4.779-784.1988. View

Ma C, Yin W, Cai B, He M, Wu J, Wang J . WITHDRAWN: Activation of TLR4/NF-kappaB signaling pathway in early brain injury after subarachnoid hemorrhage. Neurol Res. 2009; . DOI: 10.1179/016164109X12445616596283. View

Akira S, Hemmi H . Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003; 85(2):85-95. DOI: 10.1016/s0165-2478(02)00228-6. View

Rossignol D, Lynn M . Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res. 2003; 8(6):483-8. DOI: 10.1179/096805102125001127. View

Rossignol D, Lynn M . TLR4 antagonists for endotoxemia and beyond. Curr Opin Investig Drugs. 2005; 6(5):496-502. View

10.

Kaneko K, Ueda R, Nemoto H, Iijima H, Yoshimura T . Disposition of a synthetic analogue of lipid A (E5564) in rats. Xenobiotica. 2003; 33(3):323-39. DOI: 10.1080/0049825021000058097. View

11.

Reinhart K, Gluck T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J . CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med. 2004; 32(5):1100-8. DOI: 10.1097/01.ccm.0000124870.42312.c4. View

12.

Abraham E, Laterre P, Garg R, Levy H, Talwar D, Trzaskoma B . Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005; 353(13):1332-41. DOI: 10.1056/NEJMoa050935. View

13.

Opal S, Scannon P, Vincent J, White M, Carroll S, Palardy J . Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999; 180(5):1584-9. DOI: 10.1086/315093. View

14.

Agnese D, Calvano J, Hahm S, Coyle S, Corbett S, Calvano S . Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis. 2002; 186(10):1522-5. DOI: 10.1086/344893. View

15.

Andersson U, Wang H, Palmblad K, Aveberger A, Bloom O, Erlandsson-Harris H . High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000; 192(4):565-70. PMC: 2193240. DOI: 10.1084/jem.192.4.565. View

16.

Kim H, Park B, Kim J, Kim S, Lee J, Oh S . Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007; 130(5):906-17. DOI: 10.1016/j.cell.2007.08.002. View

17.

Kaneko K, Ueda R, Kikuchi K, Sano Y, Yoshimura T . Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. 2000; 736(1-2):67-75. DOI: 10.1016/s0378-4347(99)00438-7. View

18.

Sweeney D, Danner R, Eichacker P, Natanson C . Once is not enough: clinical trials in sepsis. Intensive Care Med. 2008; 34(11):1955-60. DOI: 10.1007/s00134-008-1274-6. View

19.

Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H . Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol. 2009; 24(6):1089-94. DOI: 10.1111/j.1440-1746.2008.05770.x. View

20.

Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2(8):675-80. DOI: 10.1038/90609. View